Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Company profile
Ticker
JNCE
Exchange
Website
CEO
Richard Murray
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Jounce Mass Securities, Inc. ...
JNCE stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
15 May 23
EFFECT
Notice of effectiveness
5 May 23
EFFECT
Notice of effectiveness
5 May 23
25-NSE
Exchange delisting
4 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
4 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
4 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
4 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
4 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
4 May 23
S-8 POS
Registration of securities for employees (post-effective amendment)
4 May 23
Transcripts
JNCE
Earnings call transcript
2022 Q3
10 Nov 22
JNCE
Earnings call transcript
2022 Q2
5 Aug 22
JNCE
Earnings call transcript
2022 Q1
7 May 22
JNCE
Earnings call transcript
2021 Q4
2 Mar 22
JNCE
Earnings call transcript
2021 Q3
4 Nov 21
JNCE
Earnings call transcript
2021 Q2
6 Aug 21
JNCE
Earnings call transcript
2021 Q1
4 May 21
JNCE
Earnings call transcript
2020 Q4
28 Feb 21
JNCE
Earnings call transcript
2020 Q3
6 Nov 20
JNCE
Earnings call transcript
2020 Q2
7 Aug 20
Latest ownership filings
SC 13G/A
Deep Track Capital, LP
14 Feb 24
SC 13G
Opaleye Management Inc.
9 Feb 24
SC 13G/A
Cowen Financial Products LLC
2 Feb 24
4
Change in insider ownership
5 May 23
4
KEVIN C TANG
5 May 23
3
Initial statement of insider ownership
5 May 23
SC 13D/A
TANG CAPITAL PARTNERS LP
5 May 23
4
Luisa Salter-Cid
4 May 23
4
Jigar Raythatha
4 May 23
4
RICHARD /CA/ MURRAY
4 May 23
Financial summary
Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 151.84 mm | 151.84 mm | 151.84 mm | 151.84 mm | 151.84 mm | 151.84 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 4.35 mm | (no burn) | 2.41 mm |
Cash used (since last report) | n/a | n/a | n/a | 67.98 mm | n/a | 37.58 mm |
Cash remaining | n/a | n/a | n/a | 83.86 mm | n/a | 114.27 mm |
Runway (months of cash) | n/a | n/a | n/a | 19.3 | n/a | 47.5 |
Institutional ownership, Q2 2023
25.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 0 |
Closed positions | 80 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 1.02 bn |
Total shares | 13.34 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
GILD Gilead Sciences | 5.54 mm | $55.73 mm |
Cowen Financial Products | 3.65 mm | $4.05 mm |
BMY Bristol-Myers Squibb | 3.46 mm | $17.25 mm |
Opaleye Management | 669.94 k | $917.82 mm |
California State Teachers Retirement System | 15.67 k | $28.98 mm |
Tang Capital Partners | 10.00 k | $19.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 May 23 | Kamen Robert | Common Stock | Dispose U | Yes | No | 0 | 33,875 | 0.00 | 0 | |
3 May 23 | Kamen Robert | Common Stock | Dispose U | No | No | 0 | 60,975 | 0.00 | 0 | |
3 May 23 | Kamen Robert | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.8 | 20,000 | 56.00 k | 0 |
3 May 23 | Kamen Robert | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.27 | 15,700 | 114.14 k | 0 |
3 May 23 | Kamen Robert | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.58 | 15,700 | 119.01 k | 0 |
3 May 23 | Kamen Robert | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.46 | 15,700 | 70.02 k | 0 |
3 May 23 | Kamen Robert | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.92 | 13,550 | 107.32 k | 0 |
3 May 23 | Kamen Robert | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 9.56 | 10,840 | 103.63 k | 0 |
3 May 23 | Duncan Barbara Gayle | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.8 | 20,000 | 56.00 k | 0 |
3 May 23 | Duncan Barbara Gayle | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.27 | 15,700 | 114.14 k | 0 |